Pacira BioSciences Stock (NASDAQ:PCRX)
Previous Close
$16.60
52W Range
$11.16 - $35.95
50D Avg
$15.81
200D Avg
$23.05
Market Cap
$768.32M
Avg Vol (3M)
$838.03K
Beta
0.82
Div Yield
-
PCRX Company Profile
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
PCRX Performance
Peer Comparison
Ticker | Company |
---|---|
HCM | HUTCHMED (China) Limited |
ITCI | Intra-Cellular Therapies, Inc. |
RDY | Dr. Reddy's Laboratories Limited |
ANIP | ANI Pharmaceuticals, Inc. |
PAHC | Phibro Animal Health Corporation |
IXHL | Incannex Healthcare Limited |
SSIC | Silver Spike Investment Corp. |
DCPH | Deciphera Pharmaceuticals, Inc. |
PBH | Prestige Consumer Healthcare Inc. |
ALKS | Alkermes plc |
COLL | Collegium Pharmaceutical, Inc. |
EGRX | Eagle Pharmaceuticals, Inc. |